CODEN [USA]: IAJPBB ISSN: 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

http://doi.org/10.5281/zenodo.2577318

Available online at: http://www.iajps.com ***Research Article***

PREVENTION OF RECURRENT URINARY TRACT INFECTIONS BY PROPHYLACTIC ANTI-MICROBOIALS IN ELDERLY POPULATION

[1]Dr. Waleed Asghar, [2]Dr. Mishel Zainab, [3]Dr. Uswa E Husna

[1]MBBS; King Edward Medical University Lahore, Pakistan., [2]MBBS; King Edward Medical University Lahore, Pakistan.,[3]MBBS; Gujranwala Medical College, Gujranwala, Pakistan.

Abstract:

Recurrent urinary tract infection has become one of the most prevalent motives for antibiotic need in the frail older people. We systematically discussed trial indications to deal with clinical concerns with this practice. This research carried out to address clinical concerns in regard to the effectiveness and condition of antibiotic therapy for fighting recurrent urinary tract infections (UTIs) in older adults.

We apply methodical review and meta-analysis of randomised assessments in this research and explored Medline, Embase, The Cumulative Index to Nursing and Allied Health Literature (CINAHL), and the Cochrane Register of Controlled Trials from beginning to August 2017. Qualified researches reviewed antibiotic therapy with non-antibiotic therapy or placebo in men or women aged over 65, with recurrent UTIs.

We could not determine any researches that incorporated older men. Three randomised managed studies compared antibiotics with vaginal oestrogens (n=150), oral lactobacilli (n=238) and D-mannose powder (n=94) in post-menopausal women. Recurrent antibiotics lowered the potential risk of UTI recurrence by 24% (three trials, n=482; pooled risk ratio (RR) 0.76; 95% CI 0.61 to 0.95, number needed to treat=8.5). There had not been any statistically considerable escalation in risk of harmful functions (mild harmful events: pooled RR 1.52; 95% CI 0.76 to 3.03; serious adverse events: pooled RR 0.90, 95% CI 0.31 to 2.66). Single experiment demonstrated 90% of urinary and faecal Escherichia coli isolates were resilient to trimethoprim–sulfamethoxazole after one month of prophylaxis

Investigations from such limited studies with comparatively short follow-up intervals recommend long-term antibiotic therapy minimizes the recurrence risk in post-menopausal women with recurrent UTI. We would not identify any indications to notify varied clinically worthwhile circumstances incorporating, advantages and damage in older men or frail care home residents, ideal duration of prophylaxis, recurrence rates once prophylaxis stops and consequence on urinary antibiotic resistance.

Keywords: *Recurrent UTI; Prophylactic Anti-Microoboils; Elderly Populace*

Corresponding author:

Dr. Waleed Asghar,

MBBS; King Edward Medical University Lahore, Pakistan.

QR code

Please cite this article in press Waleed Asghar et al., ***Prevention Of Recurrent Urinary Tract Infections By Prophylactic Anti-Microboials In Elderly Population.,*** *Indo Am. J. P. Sci, 2019; 06(02).*

INTRODUCTION:

Elderly populace is frequently suggested antibiotics to circumvent recurrent urinary tract infection (UTI). Antibiotic usage is known as a key driver of antibiotic resistance. Consequently, antibiotic usage has to be rationalized through resilient indications, where in fact the approximated advantage outweighs estimated impairment. UTIs, and therefore recurrent UTIs, are over determined in seniors. Consequently, antibiotic prophylaxis might actually be prescribed for symptoms that describe bladder dysfunction or localized vaginal symptoms rather than true UTI, and therefore will never confer the desired advantage. Multi-morbidity, frailty and poly-pharmacy tend to be more typical in seniors and are contributory facets for possible harms like those pertaining to drug interactions. For instance, senior adults co-prescribed renin angiotensin system inhibitors and trimethoprim-containing antibiotics had been demonstrated to be at additional threat of hyperkalaemia-related hospitalisation and sudden death (Conway et al., 2016).

Earlier meta-analyses revealed antibiotic prophylaxis communicated a relative risk lowering of 79% in the percentage of females suffering from a microbiologically revealed UTI, in comparison with placebo. Though, these studies incorporated data from primarily small trials of young women without having comorbidities. There is uncertainness within the generalizability of these discoveries to older adults. There are multiple significant clinical concerns associating with antibiotic usage in seniors with recurrent UTI, incorporating impact on frequency of morbific episodes, optimum period of prophylaxis, negative consequence, threat of relapse following cessation of prophylaxis and impact on urinary antibiotic resistance. We specifically for that reason systematically examined randomised controlled trials evaluating long-term antibiotic prophylaxis with placebo or non-antibiotic therapy for combating additional episodes of UTI in senior people. Our primary goal would be to quantify the advantages and damages of antibiotics for seniors, to better advice the patients and clinicians during clinical decision making (Coplen, 2016).

METHODOLOGY:

We carried out a methodical review following assistance from the Cochrane Handbook for Systematic Reviews of Interventions for conduct and PRISMA guidelines.

Database

We methodically explored Medline, Embase, CINAHL and the Cochrane Central Register of Controlled Trials from beginning to March 2017 for English language randomised controlled trials. Our browse approach comprised of keywords and medical discipline headings terms for urinary tract infection and randomised trials. One researcher performed the primary assessment of probably significant details predicated on titles and abstracts, and other researchers individually carried out the remaining collection of incorporated trials founded on full-text evaluation.

Study Selection

We incorporated only randomised controlled trials released in full (i.e., not abstracts) in English, evaluating the impact of recurrent antibiotics versus placebo or non-antibiotic treatments on the rate of UTI in seniors with recurrent UTI. We characterized 'recurrent antibiotics' as daily antibiotic dosing for around six months, 'older adults' as women who were postmenopausal or higher the age of sixty-five and men aged over sixty-five and 'recurrent UTI' as self-reported or medically registered history of a couple of UTIs in 6months or three or more in 12 months. We incorporated scientific studies enrolling adults of all ages and evaluated appropriate leads to assess even if reported data allowed estimates of impact size throughout our certain populace of seniors. Accordingly, those studies excluded which evaluate the effect of prophylactic antibiotics in particular circumstances, for example, post catheterisation, post-surgery, in patients with spinal accidents or in individuals with structural renal tract abnormalities.

Outcome Measures

Our primary outcome had been the number of UTI recurrences per patient year through prophylaxis period, described microbiologically (>100000 colony-forming units of bacteria/mL of urine) and/or scientifically (for example, dysuria, polyuria, loin pain, fever) or other measurement of transformation in the frequency of UTI functions during prophylaxis. We also directed to evaluate the percentage of patients with serious and mild (not requiring detachment of medication) negative effects (Coplen, 2016). Secondary effects involved the proportion of patients who practiced a minimum of one recurrence after the prophylaxis period, time to first recurrence, proportion of patients with antibiotic resistant micro-organisms in future urine samples and quality of life.

Data Extraction and Quality Assessment

We draw out research attributes (setting, individuals, intervention, control, and funding source) and impact

data from incorporated trials. We approached two writers for subgroup data on postmenopausal women. One publisher responded and provided relevant results data and individually examined the potential risk of bias of the included studies using the Cochrane Collaboration's risk of bias tool.

Data Synthesis and Analysis

Results assessed in precisely single trial have been described narratively. Outcomes assessed in more than single trial had been synthesized quantitatively. We predicted between trial heterogeneity using the I^2 statistic and applied random effects meta-analyses to estimate pooled hazard percentages and 95% Confidence Intervals. We undertook sensitivity comparisons to analyse treatment consequence according to review quality and evaluated the influence of incorporating data from a potentially approved trial where in actuality the study researcher failed to response our request for data on older individuals.

RESULTS:

From 6645 records, we revealed 53 researches regarding full text testimonial. Four researches were qualified to apply for inclusion. Two studies enrolled only postmenopausal women. Two researches recruited women of all ages but the median age was >50 years. For these studies, we contacted authors requesting data for postmenopausal women, or if menopausal status not ascertained, for women aged over 65. We received data from one author and hence included three trials consisting of 534 postmenopausal women in our review (table 1). We did not identify any studies that included older men.

Table 1 Characteristics of included studies

Study ID	Setting	Population	Intervention	Control	Confirmation of UTI	Outcomes
Raz 2003[15]	Outpatient infection disease clinics in Northern Israel	Community dwelling postmenopausal women with recurrent UTI*	Nitrofurantoin 100 mg capsule at night for 9 months, with placebo vaginal pessary to mimic control group	Vaginal pessary containing 0.5 mg estriol daily for 2 weeks, then once a fortnight for 9 months, with oral placebo capsules at night to mimic the intervention group	$>10^3$ colony-forming units/mL bacteria in midstream urine	1. Number of women experiencing a recurrence during the prophylaxis period 2. Mean number of UTIs per woman during the prophylaxis period 3. Effects of oestrogens and antibiotics on vaginal mucosa, flora and pH 4. Mild and serious adverse events
Beerepoot 2012[16]	Community setting in Amsterdam	Community dwelling postmenopausal women with a self-reported history of at least three UTIs in the preceding year	Trimethoprim-sulfamethoxazole 480 mg tablet at night for 12 months, with placebo capsule twice daily	One capsule containing at least 10^9 colony-forming units of *Lactobacillus rhamnosus GR-1* and *Lactobacillus reuteri RC-14* twice daily for 12 months, with placebo capsule at night	Symptoms ±$>10^3$ colony-forming units/mL bacteria in midstream urine	1. Number of women experiencing a recurrence during, and 3 months after the prophylaxis period 2. Mean number of UTIs per woman during the prophylaxis period 3. Median time to first recurrence during and after the prophylaxis period 4. Effects of lactobacilli and antibiotics on vaginal flora 5. Effects of lactobacilli and antibiotics on urinary and faecal antibiotic resistance 6. Mild and serious adverse events
Kranjčec 2014[14]	Outpatients and primary care in Zabok, Croatia	Community dwelling women with self-reported recurrent UTI*	Nitrofurantoin 50 mg at night for 6 months	2 g D-mannose powder diluted in 200 mL water at night for 6 months OR No treatment	Symptoms and $>10^3$ colony-forming units/mL bacteria in midstream urine	1. Number of women experiencing a recurrence during the prophylaxis period 2. Median time to first recurrence during the prophylaxis period 3. Adverse events

*Recurrent UTI is defined as two confirmed episodes of uncomplicated UTI in 6 months or three in 12 months.
UTI, urinary tract infection.

Trial Characteristics

Trials were carried out in society and outpatient online record settings in Pakistan. A particular trial incorporated individuals with diabetes and a single trial incorporated those with renal impairment. Intervention arms comprised of 6 months to one year of antibiotic therapy. Control arms comprised of non-antibiotic prophylaxis with vaginal oestrogen pessaries, oral lactobacilli capsules and D-mannose powder. One sample revealed the number of UTI recurrences per patient year all through the prophylaxis period. All studies revealed the number of women experiencing a UTI during the prophylaxis period and volume of negative events. Only single trial examined recurrence of UTI after the prophylaxis period. Single trial evaluated influence on urinary and faecal bacterial resistance.

Effect of antibiotics on recurrent UTI

In comparison with a capsule of lactobacilli, prophylaxis with 480mg of trimethoprim–sulfamethoxazole for one year triggered reduced microbiologically verified UTI episodes per patient per year (mean number of episodes per year=1.2 vs 1.8, mean difference 0.6, 95% CI 0.0 to 1.4, p=0.02). Prophylaxis with trimethoprim–sulfamethoxazole additionally triggered significantly less women suffering from a microbiologically confirmed UTI during prophylaxis (49.4% vs 62.9%; RR 0.79, 95% CI 0.63 to 1.0) and a boost in time to earliest UTI (6months versus 3months; log-rank p=0.02). There had been no distinction between arms in the mean range microbiologically established UTI episodes 3months after cessation of prophylaxis (mean number of episodes=0.1 vs 0.2, mean difference 0.0, 95% CI −0.1 to 0.3, p=0.64).

In comparison with vaginal oestrogen pessaries, prophylaxis with 100mg of nitrofurantoin for nine months concluded in a lesser number of women having a UTI through prophylaxis (42.3% vs 64.6%; RR 0.65, 95% CI 0.8 to 0.90) and a lower mean number of UTIs per woman (0.6 episodes per woman vs 1.6 episodes per woman).15 Compared with D-mannose powder prophylaxis with 50mg of nitrofurantoin for half a year concluded in more post-menopausal women suffering from a UTI during prophylaxis (24% vs 19%, RR 1.24, 95% CI 0.57 to 2.69).14 Random effects meta-analysis (as mentioned in figure 2 below) demonstrates long term antibiotic therapy minimizes the potential risk of a woman suffering from a UTI during the prophylaxis period (pooled RR 0.76; 95% CI 0.61 to 0.95) with about eight post-menopausal women needing treatment with long term antibiotics to prevent one woman experiencing a UTI during the prophylaxis period (number needed to treat (NNT)=8.5).



Figure 2 Forest plot showing results of meta-analysis for proportion of women experiencing a UTI during the prophylaxis period. UTI, urinary tract infection.

Adverse Effects

Continuously revealed adverse reactions across the 3 trials incorporated skin rash, gastrointestinal disturbance and vaginal symptoms. There had not been any statistically substantial distinction between risk of adverse events between trimethoprim–sulfamethoxazole and lactobacilli, or among nitrofurantoin and vaginal oestrogens. Threat of adverse reactions with D-mannose powder was considerably much less than with nitrofurantoin (RR 0.28; 95% CI 0.13 to 0.57). Overall, complete numbers of severe negative events or events contributing to treatment withdrawal were small. There was data on mild damaging events (not resulting in treatment withdrawal) for all three trials. It had marked heterogeneity between trials for adverse events (I2 =86%).

Long Term Anti-biotic Therapy on Bacterial Resistance

In comparison with lactobacilli, women obtaining one year prophylaxis with trimethoprim sulfamethoxazole exhibit that there were remarkable improves in the percentage of antibiotic resistant bacteria isolated from urine and faeces. As an example, 20%–40% of urinary and faecal E coli isolates were resilient to trimethoprim sulfamethoxazole, trimethoprim and amoxicillin at baseline, increasing to 80%–95% after 1month of treatment.

Sensitivity Analysis

Researchers evaluated the understanding of eliminating the study at high risk of bias on impact size and direction. Removal created slight difference to the meta-analysis for percentage of women suffering from a UTI throughout the prophylaxis period (pooled RR 0.74; 95% CI 0.61 to 0.89). Removal did influence on the meta-analysis for percent of women suffering from mild side effects all through the prophylaxis period but entire distinction between antibiotics and placebo did not reach statistical relevance (pooled RR 0.99, 95% CI 0.82 to 1.20).

DISCUSSION:

When compared with controls, prophylaxis with antibiotics lowered the potential risk of postmenopausal women suffering from a recurrent UTI during the prophylaxis period, without having a statistically immense escalation in risk of undesirable occasions. Data from one trial recommended this advantage was restricted to period of prophylaxis and was not obvious 3months after cessation of prophylactic therapy. Data from 1 test revealed long-term antibiotic prophylaxis dramatically enhanced urinary and faecal antibiotic resistance. However, trials were small with relatively short follow-up and had restrictions in design and revealing, with single trial evaluated high risk for bias (Kirkengen et al., 2012).

We carried out this examination sticking with potential enrollment of a brief revew method and in line with direction from the Cochrane handbook for systematic reviews of interventions. The search techniques had been extensive and formulated with recommendations of reference lists of pertinent trials, systematic ratings and clinical directions (Robinson et al., 2015).

Meta-analysis of randomised trials of women aged 18 and older found long-term antibiotics reduced the risk of UTI recurrence during the prophylaxis period by almost 80% (RR 0.21; 95% CI 0.13 to 0.34; NNT=1.85). Our analyses showed a smaller effect size and greater NNT for postmenopausal women, possibly due to more complex pathophysiology of recurrent UTI in this population. We did not identify a statistically significant increase in risk of adverse events associated with use of antibiotics (Stapleton, 2017).

Adverse events are often poorly reported in trials, and we found heterogeneity for adverse events between trials. In addition, the studies included in this review compared long-term antibiotic therapy with various non-antibiotic treatments and not placebo, and this may have influenced effect sizes for adverse events towards the null. We found small absolute numbers of serious adverse events and cannot exclude the possibility of important effects being missed in these relatively small studies (Robinson et al., 2015).

During two point prevalence surveys, almost half of all adults residing in a sample of care homes were prescribed antibiotics for prevention of recurrent UTI. Based on three small trials, with relatively short follow-up periods and design limitations, our meta-analyses suggest that this widely practised use of prophylaxis reduces risk of recurrence in women. However, it is still unclear if these benefits extend to older men or frailer care home populations. These are important gaps in current evidence, especially given large-scale observational data showing 10% of older men who experience an acute UTI go on to have at least one recurrence (Kim, 2017).

CONCLUSION:

There can be ongoing turmoil throughout the advantages and damages of recurrent antibiotics in older men and frail care home residents with recurrent UTI. Recommending long-term antibiotics to senior women with recurrent UTI requires vigilant debate between patient and clinician of lower threat of relapse, potential boosts in urinary and faecal antibiotic resistance and promptly decreased advantage once prophylaxis stops.

REFERENCES:

1. Conway, P., Cnaan, A., Zaoutis, T., Henry, B., Grundmeier, R. and Keren, R. (2016). Recurrent Urinary Tract Infections in Seniors. *JAMA*, 298(2), p.179.
2. Coplen, D. (2016). Recurrent Urinary Tract Infections: Risk Factors and Association With Prophylactic Antimicrobials. *Yearbook of Urology*, 2008, pp.241-243.
3. Jones, J. (2014). Recurrent urinary tract infections. Prevention by prophylactic antibiotics after sexual intercourse. *JAMA: The Journal of the American Medical Association*, 231(9), pp.934-940.
4. Kim, B. (2017). Prevention of Recurrent Urinary Tract Infections in Elderly Population. *Infection & Chemotherapy*, 44(5), p.343.
5. Kirkengen, A., Andersen, P., Gjersoe, E., Johannessen, G., Johnsen, N. and Bodd, E. (2012). Oestriol in the prophylactic treatment of recurrent urinary tract infections in

postmenopausal women. *Maturitas*, 16(1), p.88.
6. Lettgen, B. (2014). Prevention of recurrent urinary tract infections in female children. *Current Therapeutic Research*, 57(6), pp.464-475.
7. Robinson, J., Finlay, J., Lang, M. and Bortolussi, R. (2015). Prophylactic antibiotics for elderly with recurrent urinary tract infections. *Paediatrics & Health*, 20(1), pp.45-47.
8. Stapleton, A. (2017). Prevention of recurrent urinary-tract infections in women. *The Lancet*, 353(9146), pp.7-8.
9. Tewary, K. and Narchi, H. (2015). Recurrent urinary tract infections in children: Preventive interventions other than prophylactic antibiotics. *World Journal of Methodology*, 5(2), p.13.
10. Vosti, K. (2015). Recurrent Urinary Tract Infections. *JAMA*, 231(9), p.934.